TY - DATA T1 - Triage strategy used in this study. PY - 2018/06/12 AU - Johan A. Kers AU - Anthony W. DeFusco AU - Jae H. Park AU - Jin Xu AU - Mark E. Pulse AU - William J. Weiss AU - Martin Handfield UR - https://plos.figshare.com/articles/figure/Triage_strategy_used_in_this_study_/6494792 DO - 10.1371/journal.pone.0197467.g002 L4 - https://ndownloader.figshare.com/files/11941250 KW - substitution variants KW - performer KW - OG 716 KW - lantibiotic Mutacin 1140 KW - fit-for-purpose lantibiotic KW - vivo testing KW - novel antibiotics KW - novel lantibiotic KW - infections Lantibiotics KW - MU 1140-derived variants KW - novel mechanism KW - CDI KW - hamster model KW - CDAD KW - 3 weeks post infection KW - biologically-relevant systems N2 - High-throughput activity screening used robotic spotting and an optical scanner for the determination of the zones of inhibition. MIC testing provided specific activity values for the determination of the potency. Stability testing performed using biologically-relevant substrates. In vivo efficacy performed in the Golden Syrian hamster model of CDAD. See Materials and Methods section for details. Legend: FaSSGF, fasted-state simulated gastric fluid; FaSSIF, fasted-state simulated intestinal fluid. ER -